SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
Status:
Active, not recruiting
Trial end date:
2023-06-12
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of intratumoral injection of SD-101 and
BMS-986178 in treating patients with solid malignancies that have spread to other places in
the body. The TLR9 agonist SD-101 may stimulate the immune system in different ways and stop
cancer cells from growing. BMS-986178 is a monoclonal anti-OX40 antibody that enhances the
activation of T cells, immune cells that are important for fighting tumors. Giving TLR9
agonist SD-101 together with anti-OX40 antibody BMS-986178 may work better in treating
patients with advanced solid tumors.